- Codexis, Inc. (CDXS)
Codexis was founded with the simple idea that we could engineer enzymes better than anyone else Through our CodeEvolver® technology, we solve problems our customers can’t overcome using traditional chemical processes for pharmaceutical biocatalysis and enzymatic siRNA manufacturing
- Codexis, Inc. (CDXS) - Yahoo Finance
Find the latest Codexis, Inc (CDXS) stock quote, history, news and other vital information to help you with your stock trading and investing
- Codexis - Wikipedia
In 2020, Takeda Pharmaceutical announced a collaboration with Codexis to research and create gene therapies for rare diseases, including lysosomal storage disorders
- Codexis, Inc. Common Stock (CDXS) - Nasdaq
Discover real-time Codexis, Inc Common Stock (CDXS) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions Stay ahead with Nasdaq
- Codexis Inc. Stock Quote (U. S. : Nasdaq) - MarketWatch
Codexis, Inc is an enzyme engineering company, which engages in the development and sale of therapeutics It operates through the Performance Enzymes and Novel Biotherapeutics segments
- About Us :: Codexis, Inc. (CDXS)
Codexis is uniquely positioned to expand this development by providing enzymatically synthesized siRNA constructs Our siRNA is manufactured in an aqueous (water-based) solution, which drives down cost and avoids heavy use of toxic solvents
- Jobs at Codexis Inc | Codexis Inc Careers
Learn more about working at Codexis Inc and discover our latest career opportunities
- Media Room - Innovatus Capital Partners
13, February 2024 Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones 2022 1 November 2022 CVRx Reports Third Quarter 2022 Financial and Operating Results 2 August 2022 Mdxhealth Acquires Oncotype DX® GPS Prostate Cancer Business
|